Stephanie E. Smetsers

Stephanie E. Smetsers

Auto-generated profile, based on publicly available information

Stephanie E. Smetsers

Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2023 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
MCMaria Cancio
Maria Cancio
ALAlexandre G. Troullioud Lucas
Alexandre G. Troullioud Lucas
MBMarc Bierings
Marc Bierings
EKElizabeth Klein
Elizabeth Klein
MWMoniek A. de Witte
Moniek A. de Witte
SSStephanie E. Smetsers
Stephanie E. Smetsers
Allogeneic hematopoietic cell transplantation (HCT) remains the only cure for the hematologic manifestations of Fanconi anemia (FA). We performed retrospective predictor analyses for HCT outcomes in FA for pediatric and young adult patients transplanted between 2007 and 2020 across three large referral institutions. Eighty-nine patients, 70 with bone marrow failure +/− cytogenetic abnormalities, 19 with MDS/AML, were included. Five-year overall survival (OS) was 83.2% and event-free survival (EFS) was 74%. Age ≥19, HLA mismatch and year of HCT were multivariable predictors (MVPs) for OS, EFS and treatment-related mortality (TRM). In the pediatric group, TCD was a borderline MVP (P = 0.059) with 5-year OS of 73.0% in TCD vs. 100% for T-replete HCT. The cumulative incidence of day 100 grade II-IV aGvHD and 5-year cGvHD were 5.6% and 4.6%, respectively. Relapse in the MDS/AML subgroup occurred in 4 patients (16%). Graft failure was seen in 9 patients (TCD 6/37 [16%]; T-replete 3/52 [5.7%]). Six patients developed malignancy after HCT. Survival chances after HCT for FA are excellent and associated with high engrafted survival and low toxicity. Age ≥19, HLA mismatch, year of transplant and ‘TCD in the <19 years group’ (although borderline) were found to be negative predictors for survival.

21 October 2023 in Journal of Pediatric Surgery
Verified
Journal Article
Open access
JBJette J. Bakhuizen
Jette J. Bakhuizen
FPFloor A.M. Postema
Floor A.M. Postema
RRRick R. van Rijn
Rick R. van Rijn
JSJoost van Schuppen
Joost van Schuppen
FDFloor A.M. Duijkers
Floor A.M. Duijkers
JMJohannes H.M. Merks
Johannes H.M. Merks
Background: Distinguishing congenital pulmonary airway malformations (CPAMs) from pleuropulmonary blastoma (PPB) can be challenging. Previously diagnosed patients with CPAM may have been misdiagnosed and we may have missed DICER1-associated PPBs, a diagnosis with important clinical implications for patients and their families. To gain insight in potential misdiagnoses, we systematically assessed somatic DICER1 gene mutation status in an unselected, retrospective cohort of patients with a CPAM diagnosis. Methods: In the Amsterdam University Medical Center (the Netherlands), it has been standard policy to resect CPAM lesions. We included all consecutive cases of children (age 0-18 years) with a diagnosis of CPAM between 2007 and 2017 at this center. Clinical and radiographic features were reviewed, and DICER1 gene sequencing was performed on DNA retrieved from CPAM tissue samples. Results: Twenty-eight patients with a surgically removed CPAM were included. CPAM type 1 and type 2 were the most common subtypes (n = 12 and n = 13). For 21 patients a chest CT scan was available for reassessment by two pediatric radiologists. In 9 patients (9/21, 43%) the CPAM subtype scored by the radiologists did not correspond with the subtype given at pathology assessment. No pathogenic mutations and no copy number variations of the DICER1 gene were found in the DNA extracted from CPAM tissue (0/28). Conclusions: Our findings suggest that the initial CPAM diagnoses were correct. These findings should be validated through larger studies to draw conclusions regarding whether systematic DICER1 genetic testing is required in children with a pathological confirmed diagnosis of CPAM or not. Level of Evidence: Level IV. (c) 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

3 April 2023
Verified
Other
Open access
SSStephanie E. Smetsers
Stephanie E. Smetsers
EVEunike Velleuer
Eunike Velleuer
RDRalf Dietrich
Ralf Dietrich
TWThijs Wu
Thijs Wu
ABArjen Brink
Arjen Brink
RBRuud H. Brakenhoff
Ruud H. Brakenhoff
Figure S3. Visible lesions in non-transplanted FA patients. Visible lesions were found in 27 of 110 patients (25%) with follow-up. Five patients with visible lesions (4 with LOH, 1 without LOH) developed HNSCC.

3 April 2023
Verified
Other
Open access
SSStephanie E. Smetsers
Stephanie E. Smetsers
EVEunike Velleuer
Eunike Velleuer
RDRalf Dietrich
Ralf Dietrich
TWThijs Wu
Thijs Wu
ABArjen Brink
Arjen Brink
RBRuud H. Brakenhoff
Ruud H. Brakenhoff

3 April 2023
Verified
Other
Open access
SSStephanie E. Smetsers
Stephanie E. Smetsers
EVEunike Velleuer
Eunike Velleuer
RDRalf Dietrich
Ralf Dietrich
TWThijs Wu
Thijs Wu
ABArjen Brink
Arjen Brink
RBRuud H. Brakenhoff
Ruud H. Brakenhoff

3 April 2023
Verified
Other
Open access
SSStephanie E. Smetsers
Stephanie E. Smetsers
EVEunike Velleuer
Eunike Velleuer
RDRalf Dietrich
Ralf Dietrich
TWThijs Wu
Thijs Wu
ABArjen Brink
Arjen Brink
RBRuud H. Brakenhoff
Ruud H. Brakenhoff